Subscribe To

Price Alert Latest News Economic Calendar News

AQST / Aquestive's AQST-109 Receives Fast Track Tag For Allergic Reactions

The FDA has granted Fast Track Designation to Aquestive Therapeutics Inc's (NASDAQ: AQST) AQST-109 for allergic reactions. AQST-109 is an orally delivered epinephrine-based product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Read More

Demo Live Account See Partner Details

Content Topics

Aquestive

AQST

109 Receives

Fast

Track

Allergic

Reactions

Aquestive s

Aqst 109

Stock

Posted: Mar 17 2022, 11:20

Author Name: Benzinga

AQST News

By Zacks Investment Research
November 1, 2023

Aquestive Therapeutics (AQST) Stock Falls Amid Market Uptick: What Investors Need to Know

The latest trading day saw Aquestive Therapeutics (AQST) settling at $1.54, representing a -1.91% change from its previous close.

By Zacks Investment Research
October 9, 2023

Aquestive Therapeutics (AQST) Stock Sinks As Market Gains: Here's Why

Aquestive Therapeutics (AQST) closed at $1.32 in the latest trading session, marking a -0.75% move from the prior day.

By Seeking Alpha
September 22, 2023

ARS Pharmaceuticals Vs. Aquestive Therapeutics; Neffy CRL Creates An Opportunity For Investing In Both

Both ARS Pharmaceuticals and Aquestive Therapeutics are developing non-injectable epinephrine products for anaphylaxis, with potential to capture sign

By Zacks Investment Research
September 13, 2023

Aquestive Therapeutics (AQST) Flat As Market Gains: What You Should Know

Aquestive Therapeutics (AQST) closed at $1.66 in the latest trading session, marking no change from the prior day.

By Zacks Investment Research
September 12, 2023

Aquestive's (AQST) Libervant Accepted for FDA Review, Stock Up

Aquestive (AQST) announces FDA acceptance of a regulatory application seeking approval for Libervant to treat pediatric patients with frequent seizure

By Zacks Investment Research
August 7, 2023

Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates

Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares

By Zacks Investment Research
July 26, 2023

Aquestive (AQST) to Report Q2 Earnings: What's in Store?

Aquestive's (AQST) second-quarter 2023 revenues are likely to have been driven by rising licensed product revenues.

By Seeking Alpha
July 25, 2023

Aquestive Therapeutics: Developing A Better Solution To A $1 Billion/Year Anaphylaxis Problem

Anaphylm, epinephrine sublingual film is a better solution to existing and in-development epinephrine formulations to treat anaphylaxis, a $1 billion/

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.